News articles about SAGE Therapeutics (NASDAQ:SAGE) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.971908487976 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
SAGE Therapeutics (NASDAQ:SAGE) traded up $4.03 during midday trading on Wednesday, reaching $164.13. The company had a trading volume of 700,808 shares, compared to its average volume of 669,539. The company has a market cap of $7,251.41, a price-to-earnings ratio of -23.89 and a beta of 2.98. SAGE Therapeutics has a 1-year low of $53.89 and a 1-year high of $195.97.
Several research firms have recently weighed in on SAGE. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. BMO Capital Markets reiterated an “outperform” rating and issued a $112.00 price objective (up from $85.67) on shares of SAGE Therapeutics in a research note on Friday, November 17th. Needham & Company LLC upped their price objective on SAGE Therapeutics from $100.00 to $193.00 and gave the company a “buy” rating in a research note on Thursday, December 7th. Raymond James Financial upped their price objective on SAGE Therapeutics to $109.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $198.00 price objective on shares of SAGE Therapeutics in a research note on Friday, December 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $171.21.
In related news, insider Stephen Kanes sold 44,000 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the sale, the insider now directly owns 46,348 shares in the company, valued at approximately $8,211,938.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Albert Robichaud sold 60,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total value of $9,565,800.00. Following the sale, the insider now owns 152,759 shares in the company, valued at $24,354,367.37. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 314,247 shares of company stock worth $50,465,110. 6.10% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/sage-therapeutics-sage-getting-somewhat-positive-news-coverage-report-finds.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.